Abbott Laboratories CDR (ABL0)
FSX
12.60
+0.30 (+2.44%)
Closed
Aug 24, 2026
Day's Range
12.6012.60
52 wk Range
9.2015.10
Financial Statements - ABL0 - Abbott Laboratories CDR
Revenue
44.32B▲ 23.7%
Net Income
6.52B▼ 43.0%Net Margin 14.7%
EBITDA
12.02B▲ 30.8%
Free Cash Flow
7.39B▲ 36.3%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Sales | 44.32B | 35.83B |
| Cost of Goods | 19.31B | 15.97B |
| Gross Profit | 25B | 19.85B |
 Operating Expense | - | - |
| Operating Income | 8.05B | 5.82B |
| Non-Operating Interest | - | - |
| Other Income Expense | 598M | 344.23M |
| Pre Tax Income | 8.46B | 5.99B |
| Income Tax | 1.94B | -5.45B |
| Net Income | 6.52B | 11.44B |
| EPS Basic | 0.487279 | 1.003832 |
| EPS Diluted | 0.48251 | 0.990962 |
| Basic Shares Outstanding | 13.38B | 11.40B |
| Diluted Shares Outstanding | 13.38B | 11.40B |
| Ebit | 8.95B | 6.46B |
| Ebitda | 12.02B | 9.19B |
| Net Income Continuous Operations | 6.52B | 11.44B |
| Minority Interests | - | - |
| Preferred Stock Dividends | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
